MUSTANG BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
MUSTANG BIO, INC. (MBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 3.01 million shares for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2017-11-14
- MUSTANG BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2017-09-30 was 3.50K shares.
- MUSTANG BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2017-06-30 was 0.00 shares.
- MUSTANG BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2017-03-31 was 3.01M shares.
- MUSTANG BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2016-12-31 was 1.57M shares.
- MUSTANG BIO, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2016 was 2.24M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2017-09-30 | 3.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 3.50K shares derived: sum of 2 quarters · filed 2017-11-14 | 3.01M shares 10-Q · filed 2017-11-14 | 4.59M shares derived: sum of 4 quarters · filed 2017-11-14 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 3.01M shares 10-Q · filed 2017-08-14 | 4.58M shares derived: sum of 3 quarters · filed 2017-08-14 | |
| 2017-03-31 | 3.01M shares 10-Q · filed 2017-05-15 | 4.58M shares derived: sum of 2 quarters · filed 2017-05-15 | ||
| 2016-12-31 | 1.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | 2.24M shares 10-K · filed 2017-03-31 | ||
| 2016-09-30 | 670.19K shares 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |